Introduction
============

DNA damage may be caused by ultraviolet and ionizing radiations, environmental chemical agents, and reactive oxidative stresses resulting from various metabolic processes occurring normally in the body.[@b1-ott-9-269] A variety of mutagens in the environment also cause DNA damage, DNA adducts formation, and breaks in DNA strand.[@b2-ott-9-269] If left uncorrected, damages to DNA accumulate in cells and may lead to dysregulation of the cell cycle, autonomous and uncontrolled growth and development of such invasive mechanisms, which finally lead to the development of cancer.[@b3-ott-9-269] Several mechanisms have been developed by mammalian cells, specific for each type of damage, to repair the damaged DNA, in an attempt to maintain the integrity of the genome. Moreover, the genes responsible for the gene products involved in the repair mechanisms are contemplated as possible cancer susceptibility genes.[@b4-ott-9-269],[@b5-ott-9-269] The proper functioning of the DNA repair mechanisms is essential as this is a means to preserve genomic stability and functionality. Several studies have reported that highly penetrant mutations in these genes are possible causative factors in some of the familial cancer syndromes, while a number of low-penetrant single-nucleotide polymorphisms (SNPs) may predispose to the development of different forms of cancers, including breast cancer.[@b6-ott-9-269]--[@b8-ott-9-269]

Several molecular epidemiological studies have been performed in an attempt to evaluate the relation between polymorphic sites in the different DNA repair genes and different types of cancer risk in diverse populations.[@b9-ott-9-269],[@b10-ott-9-269] Among the genes, *RAD51* has been considered as a possible candidate due to its central involvement in the repair of double-strand DNA breaks by facilitating homologous pairing and strand exchanges in recombinatory structures.[@b11-ott-9-269]--[@b13-ott-9-269] The *RAD51* gene, a highly conserved gene found in most eukaryotes, from yeast to humans, encodes for the RAD51 protein. The *RAD51* family members are homologous to the bacterial Rec A and yeast *RAD51*. The RAD51 protein is involved in homologous recombination and interacts directly with X-ray repair cross-complementing proteins 2 and 3 (XRCC2, XRCC3), Breast cancer genes 1 and 2 (BRCA1, BRCA2), and so on to form a complex that is essential during double-strand break repair and DNA cross-links (especially, XRCC2 and XRCC3) and hence plays an essential role in the maintenance of chromosome stability. Several studies have reported that the RAD51 protein exhibits reduced expression in breast cancers, both sporadic and familial, and based on these findings, it was hypothesized that the genetic mutations and polymorphisms within the *RAD51* gene may contribute to the differences observed between individuals with regard to susceptibility to breast cancer tumorigenesis.[@b2-ott-9-269],[@b8-ott-9-269],[@b14-ott-9-269],[@b15-ott-9-269] Several population-based studies have been conducted, but, interestingly, results from different studies present contradictory results in different populations.[@b15-ott-9-269]--[@b19-ott-9-269]

To the best of our knowledge, since no studies have been reported on the association between SNPs in *RAD51* and susceptibility to breast cancer development in Saudi females, we initiated this study on three SNPs in *RAD51* \[rs1801320 (G\>C), rs1801321 (G\>T), and rs2619681 (C\>T)\] in a group of Saudi breast cancer patients and compared the results with normal healthy controls. This article presents our findings and shows a close relation between the susceptibility to breast cancer development and some of the polymorphic sites in *RAD51*.

Subjects and methods
====================

The study population
--------------------

The Saudi population investigated during this study comprised 96 females (median age =48 years) suffering from breast cancer who attended the outpatient clinics of the clinical coinvestigators (HAK) at King Fahad Medical City Hospital, Riyadh, Saudi Arabia, and 96 age- and sex-matched normal healthy controls who also attended King Fahad Medical City Hospital for minor illnesses and were recruited following diagnostic exclusion of cancer or history of cancer and cancer-related diseases. The patient and control populations were from Saudi Arabian ethnicity, and the majority (86/96) had a sporadic onset. Physical examination was carried out, and demographic data, age at diagnosis, tumor grade, and receptor status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) were recorded. The Institutional Review Board of King Khalid Hospital approved the study (IRB No. 15-089E); written informed consent was obtained from all individuals included in the study.

DNA extraction protocol
-----------------------

Approximately 3 mL blood samples were collected by venipuncture in vacutainer tubes containing ethylenediaminetetraacetic acid from all subjects enrolled in the study and were stored at 4°C until required for DNA extraction. Genomic DNA was extracted using QIAmp DNA Blood Mini Kit (Qiagen N.V., Venlo, the Netherlands), and the manufacturer's instructions were followed. After extraction of the DNA, each sample was subjected to purification, and the DNA was spectrophotometrically quantitated using the NanoDrop 8000 (Thermo Fisher Scientific, Waltham, MA, USA). Purity was determined using the standard *A*~260~/*A*~280~ and *A*~260~/*A*~230~ ratios, and the DNA was stored until required for genotyping.

Genotyping
----------

Three SNPs in *RAD51* were selected and genotyped. Two SNPs \[rs1801321 (G\>T) and rs2619681 (C\>T)\] were analyzed using TaqMan allelic discrimination assay and one, rs1801320 (G\>C), was analyzed by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) (designed using PRIMER3). RFLP primers were validated by sequencing the PCR products. For TaqMan genotyping assay, the primers and probe mixture were purchased directly through the assays-on-demand service of Thermo Fisher Scientific. During analysis, 20 ng of DNA per reaction was used with 5.6 µL of 2× Universal Master Mix and 200 nM primers (Thermo Fisher Scientific). All genotypes were determined by endpoint reading on an ABI 7500 real-time PCR instrument using the Sequence Detection Software (Thermo Fisher Scientific). Negative controls were used in RFLP and TaqMan assay experiments to reduce experimental errors. [Figure 1](#f1-ott-9-269){ref-type="fig"} presents the results of genotyping using the TaqMan geno typing kit.

For rs1801320 (135G\>C) genotyping, the primers used and the fragments obtained after restriction of the PCR product with restriction endonuclease BstNI are presented in [Table 1](#t1-ott-9-269){ref-type="table"}. A total of 2.5 µL of 10× PCR buffer (Qiagen), 2 µL of 2.5 mM deoxyribonucleotide triphosphate (dNTPs) (Promega Corporation, Fitch-burg, WI, USA), 1 µL from each of primers F and R (5 pmol), 2 µL of DNA (20 ng/µL), and 0.2 µL of hot start Taq polymerase (Qiagen) were mixed, and the volume was made up to 25 µL by deionized RNase- and DNase-free water. Cycling parameters presented in Qiagen handbook were followed: initial activation was carried out at 95°C for 15 minutes, followed by 35 cycles of denaturation at 95°C for 40 seconds, annealing at 61.8°C for 40 seconds, and elongation at 72°C for 40 seconds and then the final elongation step at 72°C for 10 minutes. After amplification, the PCR product was subjected to agarose gel electrophoresis to confirm that the amplification had taken place and a 600 bp fragment was obtained. The PCR products were digested with BstNI for 2 hours at 60°C, and the fragments obtained were subjected to electrophoresis in 3% agarose gel. Ethidium bromide was incorporated in the gel for visualization of the DNA fragments under ultraviolet light. For each genotype of the tested SNP, the sizes of the fragments obtained are presented in [Table 1](#t1-ott-9-269){ref-type="table"}. [Figure 2](#f2-ott-9-269){ref-type="fig"} presents an electrophoretogram of the fragments following agarose gel electrophoresis.

As a quality control measure for verification of genotyping procedure for rs1901320 using PCR-RFLP, 5% of the samples genotyped were randomly selected and subjected to sequencing analysis. The results of the three genotypes are presented in [Figure 3](#f3-ott-9-269){ref-type="fig"} and were reproducible without any discrepancies.

Statistical analysis
--------------------

Each sample was assigned its genotype. The number of each genotype was obtained manually, and the frequencies of the genotypes and alleles were manually computed. Any deviation from Hardy--Weinberg equilibrium was checked using the website <http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl>. The frequencies of the genotypes and alleles in the cases and controls were calculated using the chi-square test and unadjusted odds ratios (ORs), and 95% confidence intervals (CIs) were calculated by Fisher's exact test (two-tailed). Statistical analysis was carried out using SPSS 21 for Windows. A *P*-value of ≤0.05 was considered statistically significant.

Results
=======

[Table 2](#t2-ott-9-269){ref-type="table"} presents the demographic data and receptor status of the breast cancer patients investigated during this study. The frequency of each genotype and its alleles was calculated in the total patients group and in the patients grouped according to the age of diagnosis, tumor status, and receptor status. The genotype and allele frequencies of the three SNPs investigated in the breast cancer patients and the controls are presented in [Table 3](#t3-ott-9-269){ref-type="table"}. For rs1801321G\>T, the majority of breast cancer patients were homozygous for the wild-type G allele and a strong relation was observed between rs1801321 polymorphism and breast cancer susceptibility. The GG genotype and G allele were strongly associated with an elevated risk of breast cancer in the Saudi population with *P*\<0.0001. The mutant T, on the other hand, seems to provide protection against breast cancer development since the frequency of the TT and GT genotype was significantly lower in the patients compared to the controls (*P*\<0.0001). For the rs1801320 G\>C, no significant differences were found in the genotype and allele frequencies for the C and G alleles in breast cancer patients and normal controls. For rs2619681 (C\>T), the homozygous CC genotype occurred at a significantly higher frequency in the breast cancer patients (*P*\<0.05). When the patients were compared to the control group, the allele frequency showed statistically significant difference (*P*\<0.05) and the OR for the T allele was 0.487. Since the frequency of the T allele was higher in the control group, it showed a protective effect against cancer development.

The cancer patients were grouped on the basis of the age of diagnosis, tumor stage, and the ER, PR, and HER2 statuses. The genotype frequencies were calculated, the allele frequencies were obtained from the different groups, and the results were compared. [Table 4](#t4-ott-9-269){ref-type="table"} summarizes the results obtained. There was no significant difference in the genotype and allele frequencies of the three SNPs in patients who had an early onset of cancer compared to those with a late onset. The frequencies of the three SNPs also did not differ in patients with different tumor grades and HER2 status (+ or −). However, the frequency of rs1801320 (135G\>C) differed in the ER+ and ER−, where the CC genotype was significantly higher in the ER− breast cancer females. Finally, the allele frequency of C allele of rs2619681 C\>T was significantly higher in the ER+ and PR+ breast cancer patients compared to that of the ER− and PR− patients. The results of rs2619681 C\>T in the PR+ and ER+ breast cancer patients in comparison to those of the PR− and ER− breast cancer patients are presented in [Table 5](#t5-ott-9-269){ref-type="table"}.

Discussion
==========

Research conducted over the last few decades has made it apparent that the pathways involved in the repair of DNA are continuously monitoring chromosomes in an attempt to correct damages caused by endogenous mutagens and exogenous agents, such as ultraviolet light or cigarette smoke. By repairing these damages, these pathways play a critical role in protecting against genetic mutations.[@b3-ott-9-269],[@b4-ott-9-269] These pathways are hence responsible for conserving the stability and integrity of the human genome.[@b3-ott-9-269]--[@b5-ott-9-269] Extensive genetic studies have been carried out on different DNA repair genes to identify possible loci predisposing to increased susceptibility to different forms of cancer.[@b9-ott-9-269],[@b16-ott-9-269],[@b20-ott-9-269]--[@b23-ott-9-269] Defects in DNA repair pathways may alter the capacity of the cell to repair damaged DNA, leading to an accumulation of DNA damages. This may be followed by unregulated cell growth and irregularities of programmed cell death and may account, in part, for the development of cancer.[@b5-ott-9-269]

Double-strand break damage in the DNA is considered as the most dangerous lesion as it may lead to cell death and may constitute a grave threat to viability of the cells and stability of the genome. Cell survival may be endangered since cell cycle progression may be permanently arrested.[@b24-ott-9-269] Any defects in these repair mechanisms may result in the accumulation of chromosomal aberrations, which may increase the susceptibility to develop cancer.[@b5-ott-9-269],[@b9-ott-9-269],[@b25-ott-9-269] The two pathways actively involved in the repair of double-strand breaks are nonhomologous end-joining and homologous recombination. Both these pathways have been investigated extensively, and several polymorphisms have been highlighted in the enzymes and proteins involved in these pathways.[@b26-ott-9-269]--[@b28-ott-9-269]

Among the many genes investigated, *RAD51* has attracted extensive attention. It is one of the key proteins for homologous recombination and plays a crucial role in homologous recombination repair of DNA double-strand breaks.[@b29-ott-9-269] The main function of RAD51 is in DNA repair, where it forms nucleoprotein filaments on single-stranded DNA, induces homologous pairing, and mediates strand exchange reactions between single- and double-stranded DNA.[@b30-ott-9-269] The gene for RAD51 (*RAD51* gene) is located on chromosome 15q15.1 in humans, and *RAD51* gene polymorphisms have attracted widespread attention. Among the many polymorphic sites, two sites have been extensively investigated. These are rs1801320, a G to C transversion at the position +135, and rs1801321, a G to T transversion at the position 172. Both these sites are located in the 5′ untranslated region and are believed to have functional relevance. They are shown to affect stability of mRNA or translational efficiency and lead to altered level and function of the polypeptide product (RAD51 protein), thus influencing the DNA repair capacity to some extent.[@b31-ott-9-269],[@b32-ott-9-269] Reduced expression of the RAD51 protein is reported in both sporadic and familial breast cancer patients, and based on these findings, it has been hypothesized that the genetic variation within the *RAD51* gene may contribute to carcinogenesis.[@b7-ott-9-269],[@b8-ott-9-269],[@b17-ott-9-269],[@b19-ott-9-269] It is suggested that these findings also explain observed interindividual differences with regard to breast cancer susceptibility.

Extensive molecular epidemiological studies on the frequency of these polymorphisms in cancer patients and healthy controls in different populations have revealed contradictory findings. With regard to both rs1801320 135G\>C and rs1801321 172G\>T, studies have shown a close association between this SNP and risk of different cancers. A few of the studies are summarized in [Tables 6](#t6-ott-9-269){ref-type="table"} and [7](#t7-ott-9-269){ref-type="table"}. In breast cancer patients, the studies also revealed contradictory results and showed both association and no association.[@b7-ott-9-269],[@b8-ott-9-269],[@b18-ott-9-269] This led to meta-analyses of the previous studies by different groups of researchers, and again, there were contradictions.[@b19-ott-9-269] These differences to some extent were related to the type of breast cancer, ie, sporadic or familial, and were due to different BRCA1 and 2 statuses of the patients. Since results of the previous studies were inconclusive, a recent extensive meta-analysis was conducted to determine the associations between *RAD51* gene polymorphisms (rs1801320 135G\>C and rs1801321 172G\>T) and risk of cancer.[@b33-ott-9-269] This meta-analysis was performed on 54 published case--control studies. Among them, 42 studies with 19,142 cases and 20,363 controls were for rs1801320 135G\>C polymorphism and 12 studies with 6,646 cases and 6,783 controls for rs1801321 172G\>T polymorphism. The overall results showed that for 135G\>C (rs1801320) polymorphism, the pooled results indicate significantly increased risk for overall cancers, especially breast cancer, while for rs1801321 172G\>T (rs1801321) polymorphism, this meta-analysis showed a decreased cancer risk in head and neck cancers.

Despite the conclusive results of the comprehensive meta-analyses, our study presents another contradictory finding in Saudi breast cancer patients. For rs1801320 135G\>C, no association was observed between the genotype and allele frequencies in the breast cancer patients and the normal controls. When the breast cancer patients were grouped according to the age of diagnosis, tumor grade, and ER, PR, and HER2 statuses of the patients, and the frequency of rs1801320 was compared in the two groups, no significant differences were identified except in those with ER+ and ER− phenotypes, where the homozygous CC genotype occurred at a higher frequency in the individuals who were ER− and the difference compared to the results in ER+ was statistically significant. On the other hand, our results in Saudis show a highly significant association of rs1801321 172G\>T with breast cancer, where the G allele was highly predisposing to breast cancer risk and almost 50% of the breast cancer patients had the GG genotype, 41.7% had the GT genotype, and only 8.3% had the TT genotype. On the other hand, none of the control group had the GG genotype, 53.13% had the TT genotype, and 46.88% had the GT genotype. The T allele was highly protective (OR =0.126; 95% CI =0.080--0.199; *P*\>0.0001).

The results of this study suggest a relation between RAD51 and susceptibility to develop breast cancer. Interestingly, a polymorphism, a G\>T transversion in the 5′ untranslated region, which probably affects the stability of mRNA of RAD51, leading to an increase in the rate of its posttranscriptional expression and hence an increase in the level of RAD51 protein decreases the risk of breast cancer. This well known affect is an interaction between several proteins, including BRCA1 and BRCA2, which are the two key players during homologous recombination. Hence, *RAD51* functions as a tumor suppressor gene. This hypothesis needs confirmation, and further detailed investigations are required to work out the mechanism.

As far as rs1801320 was concerned, the results in Saudis are in agreement with the results reported from USA, Poland, and other populations,[@b6-ott-9-269],[@b17-ott-9-269],[@b34-ott-9-269]--[@b38-ott-9-269] and the results of the meta-analysis that did not find any association between this SNP and breast cancer.

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding this work through research group project RGPVPP-081.

**Disclosure**

The authors report no conflicts of interest in this work.

![Detection of the rs1801321 (G\>T) and rs2619681 (C\>T) genotypes in *RAD51* using TaqMan genotyping assay.](ott-9-269Fig1){#f1-ott-9-269}

![Agarose gel electrophoresis of rs1801320 in *RAD51* 135G\>C variant after digestion with BstNI (the genotype is shown at the top of the electrophoretogram).](ott-9-269Fig2){#f2-ott-9-269}

![Sequence of the (**A**) wild-type allele (G), (**B**) heterozygous allele (GC), and (**C**) homozygous mutant allele (C) of rs1801320 in *RAD51* (135G\>C variant).](ott-9-269Fig3){#f3-ott-9-269}

###### 

Primers used for amplification of RAD51 SNP (rs1801320, G\>C) and fragments obtained after restriction with BstNI for the three genotypes

  ---------------------------------------------------------------------------------------------------------------------------------------------
  RAD51 (rs1801320)   5′--3′ primer sequences   Tm       Product size (bp)   RE used   Size (bp) of the fragments obtained after RE treatment
  ------------------- ------------------------- -------- ------------------- --------- --------------------------------------------------------
  RAD51 F             AAGGGAAGAGGGCAGTCTGT      61.8°C   600                 BstNI     GG: 136, 176, 161, 127 bp

  RAD51 R             CACAAGTGGACCTCAGTCT                                              GC: 136/127, 337, 176, 161 bp\
                                                                                       CC: 136, 337, 127 bp
  ---------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** SNP, single-nucleotide polymorphism; RE, restriction endonuclease; Tm, melting temperature.

###### 

Demographic data and receptor status of the patients with breast cancer

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients with cancer   Average age (years)   Tumor grade (number of patients)   ER status (number of patients)   PR status (number of patients)   HER2 status (number of patients)
  ---------------------- --------------------- ---------------------------------- -------------------------------- -------------------------------- ----------------------------------
  96                     \<40=27               I=1                                ER+ =55                          PR+ =56                          HER2+ =41

                         \>40=71               II=49\                             ER− =45                          PR− =44                          HER2− =57
                                               III=37\                                                                                              
                                               IV=1                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

###### 

Genotype and allele frequencies of studied SNPs in breast cancer patients and controls

  Genotype                 Cases          Controls       OR      95% CI         *χ*^2^   *P*-value
  ------------------------ -------------- -------------- ------- -------------- -------- -----------
  *RAD51* rs1801321 G\>T                                                                 
   Genotype frequency                                                                    
    GG                     48 (50%)       0              Ref                             
    GT                     40 (41.666%)   45 (46.875%)   0.009   0.001--0.154   38.41    \<0.0001
    TT                     8 (8.333%)     51 (53.125%)   0.002   0.000--0.030   79.28    \<0.0001
    GT + TT                48 (50%)       96 (100%)      0.005   0.000--0.086   64.00    \<0.0001
   Allele frequency                                                                      
    G                      136 (0.708)    45 (0.234)     Ref     0.080--0.199   86.54    \<0.0001
    T                      56 (0.291)     147 (0.765)    0.126                           
  *RAD51* rs1801320 G\>C                                                                 
   Genotype frequency                                                                    
    GG                     59 (59%)       60 (60%)       Ref                             
    GC                     31 (31%)       31 (31%)       1.017   0.550--1.879   0.00     0.957
    CC                     10 (10%)       9 (9%)         1.130   0.429--2.980   0.06     0.804
    GC + CC                41 (41%)       40 (40%)       1.042   0.593--1.833   0.02     0.885
   Allele frequency                                                                      
    G                      149 (0.745)    151 (0.755)    Ref     0.671--1.659   0.05     0.817
    C                      51 (0.255)     49 (0.245)     1.055                           
  *RAD51* rs2619681 C\>T                                                                 
   Genotype frequency                                                                    
    CC                     75 (79.787%)   63 (66.315%)   Ref                             
    CT                     17 (18.085%)   25 (26.315%)   0.571   0.283--1.152   2.48     0.11533
    TT                     2 (2.127%)     7 (7.368%)     0.240   0.048--1.197   3.50     0.06152
    CT + TT                19 (20.21%)    32 (33.68%)    0.499   0.258--0.964   4.35     0.03696
   Allele frequency                                                                      
    C                      167 (0.888)    151 (0.794)    Ref     0.274--0.865   6.19     0.01281
    T                      21 (0.111)     39 (0.205)     0.487                           

**Abbreviations:** SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; Ref, reference.

###### 

Comparison of the genotype and allele frequencies of the three SNPs in breast cancer patients grouped on the basis of age of diagnosis, tumor grade, ER, PR, and HER2 statuses

  Parameter                     Group        Group        Significance
  ----------------------------- ------------ ------------ --------------
  *RAD51* rs1801321 (172G\>T)                             
   Age at diagnosis             \>40 years   \<40 years   NS
   ER                           \+           −            NS
   PR                           \+           −            NS
   HER2                         \+           −            NS
   Tumor grade                  II           III          NS
  *RAD51* rs1801320 (135G\>C)                             
   Age at diagnosis             \>40 years   \<40 years   NS
   ER                           \+           − ↑CC        \<0.05
   PR                           \+           −            NS
   HER2                         \+           −            NS
   Tumor grade                  II           III          NS
  *RAD51* rs2619681 C\>T                                  
   Age at diagnosis             \>40 years   \<40 years   NS
   ER                           \+ ↑C        −            \<0.05
   PR                           \+ ↑C        −            \<0.05
   HER2                         \+           −            NS
   Tumor grade                  II           III          NS

**Abbreviations:** SNP, single-nucleotide polymorphism; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; NS, not significant.

###### 

Genotype and allele frequency of RAD51 rs2619681 C\>T in patients with different PR and ER statuses

  RAD51 rs2619681 C\>T                                             OR     CI           *χ*^2^ (*P*-value)   *P*-value
  ---------------------- -------------------- -------------------- ------ ------------ -------------------- -----------
                         **PR**+**, N (%)**   **PR**−**, N (%)**                                            
  Genotype frequency                                                                                        
   CC                    47 (87%)             28 (70%)             2.88   1.01--8.17   4.136                0.041
   CT                    7 (13%)              10 (25%)             0.45   0.15--1.30   2.247                0.133
   TT                    0                    2 (5%)                                                        
  Allele frequency                                                                                          
   C                     101 (0.935)          66 (0.825)           3.06   0.17--7.98   5.623                0.017
   T                     7 (0.064)            14 (0.175)           0.33   0.13--0.85   5.623                0.017
   Total number          108                  80                                                            
                         **ER**+**, N (%)**   **ER**−**, N (%)**                                            
  Genotype frequency                                                                                        
   CC                    46 (86.8%)           29 (70.7%)           2.72   0.96--7.71   3.697                0.054
   CT                    7 (13.2%)            10 (24.5%)           0.47   0.16--1.37   1.951                0.162
   TT                    0                    2 (4.8%)                                                      
  Allele frequency                                                                                          
   C                     99 (0.933)           68 (0.829)           2.91   1.12--7.59   5.107                0.023
   T                     7 (0.066)            14 (0.170)           0.34   0.13--0.90   5.107                0.023
   Total number          106                  82                                                            

**Abbreviations:** PR, progesterone receptor; ER, estrogen receptor; OR, odds ratio; CI, confidence interval.

###### 

Frequency of rs1801321 172G\>T in RAD51 in different types of cancer in different populations

  Cancer types                  Population   No of patients studied         Effect           References
  ----------------------------- ------------ ------------------------------ ---------------- ------------------
  *RAD51* rs1801321 (172G\>T)                                                                
   Ovarian cancer               Poland       Patients =210                  No association   [@b39-ott-9-269]
   Ovarian cancer               Polish       Patients =120, controls =120   No association   [@b40-ott-9-269]
   Breast cancer                Caucasian    Patients =289, controls =548   No association   [@b41-ott-9-269]
   Colorectal cancer            Poland       Patients =320, controls =320   No association   [@b42-ott-9-269]
   Endometrial cancer           Polish       Patients =240, controls =240   No association   [@b43-ott-9-269]

###### 

Frequency of rs1801320 135G\>C in RAD51 in different types of cancer in different populations

  Cancer types             Population   No of patients studied                                                                                     Effect        References
  ------------------------ ------------ ---------------------------------------------------------------------------------------------------------- ------------- ------------------
  Larynx cancer            Polish       Patients =253                                                                                              Association   [@b44-ott-9-269]
  Breast cancer            Polish       Patients =790                                                                                              Association   [@b45-ott-9-269]
  Endometrial cancer       Polish       Patients =230                                                                                              Association   [@b46-ott-9-269]
  Sporadic breast cancer   Polish       Patients =700, controls =708                                                                               Association   [@b47-ott-9-269]
  Ovarian cancer           Poland       Patients =210                                                                                              Association   [@b39-ott-9-269]
  Breast cancer            Serbian      Patients (BRCA−) with history of cancer =48, patients without history of cancer =107, control group =114   Association   [@b48-ott-9-269]
  Esophageal cancer        Chinese      Patients =123, controls =61                                                                                Association   [@b7-ott-9-269]
  Ovarian cancer           Polish       Patients =120, controls =120                                                                               Association   [@b40-ott-9-269]
  Breast cancer            Iranian      Patients =294, controls =315                                                                               Association   [@b8-ott-9-269]
  Endometrial cancer       Polish       Patients =240, controls =240                                                                               Association   [@b43-ott-9-269]
  Acute myeloid leukemia   Chinese      Patients =806, controls =704                                                                               Association   [@b49-ott-9-269]
  Colorectal cancer        Poland       Patients =320, controls =320                                                                               Association   [@b42-ott-9-269]

**Abbreviation:** BRCA, breast cancer.
